This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Xanthan gum
- DrugBank Accession Number
- DB11253
- Background
Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol. The major constituents include D-glucose, D-mannose, and D-glucuronic acid. Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image NoSno Liquid 0.05 mL/44mL Nasal K&J.C Co., Ltd 2012-03-03 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Gel Xanthan gum (10 mg/50mg) + Glycerin (7.5 mg/50mg) + Hyaluronic acid (5 mg/50mg) + Nicotinamide (7.5 mg/50mg) + Olive oil (15 mg/50mg) Gel Cutaneous Shantou Youjia E-Commerce Co.,Ltd. 2024-02-01 2024-12-31 US HydroGold 9 Xanthan gum (0.5 mg/100mg) + Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Potassium chloride (0.01 mg/100mg) + Titanium dioxide (0.43 mg/100mg) Patch Topical Bhmbg Global Branding Inc. 2018-03-09 2019-12-31 US Medi SM 24K Gold Hydrogel Peptide Mask Pack Xanthan gum (0.01 g/100g) + Adenosine (0.01 g/100g) + Butylene glycol (0.01 g/100g) + Chlorphenesin (0.01 g/100g) + Chondrus crispus (0.02 g/100g) + Glycerin (0.05 g/100g) + Glycyrrhiza glabra (0.01 g/100g) + Gold (0.01 g/100g) + Nicotinamide (0.02 g/100g) + Polysorbate 20 (0.01 g/100g) + Polysorbate 60 (0.02 g/100g) + Potassium chloride (0.02 g/100g) + Propolis wax (0.01 g/100g) + Titanium dioxide (0.01 g/100g) Emulsion Topical Mbg Inc (Korea Institute of Science Development) 2017-11-07 2018-11-07 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image HydroGold 9 Xanthan gum (0.5 mg/100mg) + Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Potassium chloride (0.01 mg/100mg) + Titanium dioxide (0.43 mg/100mg) Patch Topical Bhmbg Global Branding Inc. 2018-03-09 2019-12-31 US Medi SM 24K Gold Hydrogel Peptide Mask Pack Xanthan gum (0.01 g/100g) + Adenosine (0.01 g/100g) + Butylene glycol (0.01 g/100g) + Chlorphenesin (0.01 g/100g) + Chondrus crispus (0.02 g/100g) + Glycerin (0.05 g/100g) + Glycyrrhiza glabra (0.01 g/100g) + Gold (0.01 g/100g) + Nicotinamide (0.02 g/100g) + Polysorbate 20 (0.01 g/100g) + Polysorbate 60 (0.02 g/100g) + Potassium chloride (0.02 g/100g) + Propolis wax (0.01 g/100g) + Titanium dioxide (0.01 g/100g) Emulsion Topical Mbg Inc (Korea Institute of Science Development) 2017-11-07 2018-11-07 US NoSno Xanthan gum (0.05 mL/44mL) Liquid Nasal K&J.C Co., Ltd 2012-03-03 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TTV12P4NEE
- CAS number
- 11138-66-2
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911167
- 1307815
- Wikipedia
- Xanthan_gum
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Dry Eyes 1 somestatus stop reason just information to hide 1 Completed Treatment Dry Eye Syndrome (DES) / Lubricant Allergy / Tear Disorder 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Cutaneous Patch Topical Emulsion Topical Liquid Nasal 0.05 mL/44mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at June 12, 2020 16:53